Dr. Kevin Becker

Claim this profile

Maimonides Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
5 reported clinical trials
12 drugs studied

Area of expertise

1Lung Cancer
Kevin Becker has run 4 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I
2Non-Small Cell Lung Cancer
Kevin Becker has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage II
Stage III
Stage I

Affiliated Hospitals

Image of trial facility.
Maimonides Medical Center
Image of trial facility.
Maimonides Cancer Center

Clinical Trials Kevin Becker is currently running

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

More about Kevin Becker

Clinical Trial Related10 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Kevin Becker has experience with
  • Biospecimen Collection
  • Crizotinib
  • Carboplatin
  • Gemcitabine Hydrochloride
  • Paclitaxel
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kevin Becker specialize in?
Kevin Becker focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage III.
Is Kevin Becker currently recruiting for clinical trials?
Yes, Kevin Becker is currently recruiting for 3 clinical trials in Brooklyn New York. If you're interested in participating, you should apply.
Are there any treatments that Kevin Becker has studied deeply?
Yes, Kevin Becker has studied treatments such as Biospecimen Collection, Crizotinib, Carboplatin.
What is the best way to schedule an appointment with Kevin Becker?
Apply for one of the trials that Kevin Becker is conducting.
What is the office address of Kevin Becker?
The office of Kevin Becker is located at: Maimonides Medical Center, Brooklyn, New York 11219 United States. This is the address for their practice at the Maimonides Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.